Neoadjuvant chemotherapy with FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy for borderline resectable and resectable pancreatic cancer (PREOPANC-2): A multicenter randomized controlled trial

被引：14

作者：

Koerkamp, B. Groot ^{[1
]}

Janssen, Q. P. ^{[1
]}

van Dam, J. L. ^{[1
]}

Bonsing, B. A. ^{[2
]}

Bos, H. ^{[3
]}

Bosscha, K. P. ^{[4
]}

Haberkorn, B. C. M. ^{[5
]}

de Hingh, I. H. J. T. ^{[6
]}

Karsten, T. M. ^{[7
]}

Van der Kolk, M. B. ^{[8
]}

Liem, M. S. L. ^{[9
]}

Loosveld, O. J. L. ^{[10
]}

Patijn, G. A. ^{[11
]}

van Santvoort, H. C. M. ^{[12
]}

de Vos-Geelen, J. ^{[13
]}

van der Holt, B. ^{[14
]}

Homs, M. Y. V. ^{[15
]}

van Tienhoven, G. ^{[16
]}

Besselink, M. G. ^{[17
]}

Wilmink, H. W. ^{[18
]}

机构：

[1] Erasmus MC Canc Inst, Surg, Rotterdam, Netherlands

[2] LUMC Leiden Univ Med Ctr, Surg, Leiden, Netherlands

[3] Ziekenhuis Tjongerschans, Internal Med, Heerenveen, Netherlands

[4] Jeroen Bosch Hosp, Surg, Shertogenbosch, Netherlands

[5] Maasstad Ziekenhuis, Internal Med, Rotterdam, Netherlands

[6] Catharina Hosp, Surg, Eindhoven, Netherlands

[7] OLVG Hosp, Surg, Amsterdam, Netherlands

[8] Radboud Univ Nijmegen, Surg, Med Ctr, Nijmegen, Netherlands

[9] Med Spectrum Twente, Surg, Enschede, Netherlands

[10] Amphia Ziekenhuis Locat Molengracht, Dept Med Oncol, Breda, Netherlands

[11] Isala Hosp, Surg, Zwolle, Netherlands

[12] UMC Univ Med Ctr Utrecht, Surg, Utrecht, Netherlands

[13] Maastricht Univ Med Ctr MUMC, Dept Med Oncol, Maastricht, Netherlands

[14] Erasmus MC Canc Inst, Hematol, Rotterdam, Netherlands

[15] Erasmus MC Canc Inst, Med Oncol, Rotterdam, Netherlands

[16] Univ Amsterdam, Radiat Oncol, Amsterdam UMC, Amsterdam, Netherlands

[17] Univ Amsterdam, Surg, Amsterdam UMC, Amsterdam, Netherlands

[18] Univ Amsterdam, Med Oncol, Amsterdam UMC, Amsterdam, Netherlands

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.10.084

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA83

引用

下载

页码：S1323 / S1323

页数：1

共 50 条

[1] Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial
Janssen, Q. P.
van Dam, J. L.
Bonsing, B. A.
Bos, H.
Bosscha, K. P.
Coene, P. P. L. O.
van Eijck, C. H. J.
de Hingh, I. H. J. T.
Karsten, T. M.
van der Kolk, M. B.
Patijn, G. A.
Liem, M. S. L.
van Santvoort, H. C.
Loosveld, O. J. L.
De Vos-Geelen, J.
Zonderhuis, B. M.
Homs, M. Y., V
van Tienhoven, G.
Besselink, M. G.
Wilmink, J. W.
Koerkamp, B. Groot
BMC CANCER, 2021, 21 (01)
[2] Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial
Q. P. Janssen
J. L. van Dam
B. A. Bonsing
H. Bos
K. P. Bosscha
P. P. L. O. Coene
C. H. J. van Eijck
I. H. J. T. de Hingh
T. M. Karsten
M. B. van der Kolk
G. A. Patijn
M. S. L. Liem
H. C. van Santvoort
O. J. L. Loosveld
J. de Vos-Geelen
B. M. Zonderhuis
M. Y. V. Homs
G. van Tienhoven
M. G. Besselink
J. W. Wilmink
B. Groot Koerkamp
BMC Cancer, 21
[3] Total neoadjuvant FOLFIRINOX or gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2): A nationwide multicenter randomized controlled trial.
Janssen, Quisette
van Dam, Jacob L.
Besselink, Marc G. H.
Homs, Marjolein Y. V.
van Tienhoven, Geertjan
Wilmink, Johanna W.
Koerkamp, Bas Groot
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[4] Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial
Versteijne, Eva
van Dam, Jacob L.
Suker, Mustafa
Janssen, Quisette P.
Groothuis, Karin
Akkermans-Vogelaar, Janine M.
Besselink, Marc G.
Bonsing, Bert A.
Buijsen, Jeroen
Busch, Olivier R.
Creemers, Geert-Jan M.
van Dam, Ronald M.
Eskens, Ferry A. L. M.
Festen, Sebastiaan
de Groot, Jan Willem B.
Koerkamp, Bas Groot
de Hingh, Ignace H.
Homs, Marjolein Y., V
van Hooft, Jeanin E.
Kerver, Emile D.
Luelmo, Saskia A. C.
Neelis, Karen J.
Nuyttens, Joost
Paardekooper, Gabriel M. R. M.
Patijn, Gijs A.
van der Sangen, Maurice J. C.
de Vos-Geelen, Judith
Wilmink, Johanna W.
Zwinderman, Aeilko H.
Punt, Cornelis J.
van Tienhoven, Geertjan
van Eijck, Casper H. J.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (11) : 1220 - +
[5] Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancer: Chemotherapy or Chemoradiotherapy?
Versteijne, Eva
de Hingh, Ignace H. J. T.
Homs, Marjolein Y. V.
Intven, Martijn P. W.
Klaase, Joost M.
van Santvoort, Hjalmar C.
de Vos-Geelen, Judith
Wilmink, Johanna W.
van Tienhoven, Geertjan
FRONTIERS IN ONCOLOGY, 2022, 11
[6] Neoadjuvant Chemoradiotherapy for Resectable and Borderline Resectable Pancreatic Cancer
Attaallah, Wafi
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (28) : 3346 - +
[7] Neoadjuvant Chemoradiotherapy for Resectable and Borderline Resectable Pancreatic Cancer
Hayakawa, S.
Karasawa, K.
Fujisawa, T.
Ito, K.
Shibata, Y.
Shimizuguchi, T.
Nihei, K.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E236 - E236
[8] Neoadjuvant Gemcitabine-based Accelerated Hyperfractionation Chemoradiotherapy for Patients with Borderline Resectable Pancreatic Adenocarcinoma
Takeda, Yutaka
Nakamori, Shoji
Eguchi, Hidetoshi
Kobayashi, Shogo
Marubashi, Shigeru
Tanemura, Masahiro
Konishi, Koji
Yoshioka, Yasuo
Umeshita, Koji
Mori, Masaki
Doki, Yuichiro
Nagano, Hiroaki
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2014, 44 (12) : 1172 - 1180
[9] Neoadjuvant fractionated versus hypofractionated chemoradiotherapy in resectable and borderline resectable pancreatic cancer
Lee, Darren
Nelson, Bailey
Rai, Shesh
Rai, Jayesh
Wang, Kyle
Sohal, Davendra
Olowokure, Olugbenga Olanrele
Rojan, Adam
Patel, Sameer H.
Wilson, Gregory
Ahmad, Syed A.
Kharofa, Jordan
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[10] Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial
Goetze, Thorsten O.
Reichart, Alexander
Bankstahl, Ulli S.
Pauligk, Claudia
Loose, Maria
Kraus, Thomas W.
Elshafei, Moustafa
Bechstein, Wolf O.
Trojan, Joerg
Behrend, Matthias
Homann, Nils
Venerito, Marino
Bohle, Wolfram
Varvenne, Michael
Bolling, Claus
Behringer, Dirk M.
Kratz-Albers, Karsten
Siegler, Gabriele M.
Hozaeel, Wael
Al-Batran, Salah-Eddin
ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (6) : 4073 - 4083

← 1 2 3 4 5 →